Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
about
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerRole of MDM2 and MDMX in DNA repairRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceGefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationThe salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapyCT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer.Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomasDrug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor.Versican expression in canine carcinomas in benign mixed tumours: is there an association with clinical pathological factors, invasion and overall survival?AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall.New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.Clinical trials for lung cancer in ChinaLung cancer and lung injury: the dual role of ceramideCigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma.Drug Resistance to EGFR Inhibitors in Lung CancerAssessment of epidermal growth factor receptor status in glioblastomas.Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge.Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.GPR39 receptors and actions of trace metals on pancreatic beta cell function and glucose homoeostasis.Prediction of biomarkers of oral squamous cell carcinoma using microarray technology.Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding.[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion.Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis.Microfluidic Capture and Multiplex Immunofluorescence of Circulating Tumor Cells to Identify Cancer of Origin.Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
P2860
Q26865779-5B8072A1-D122-40C2-82B9-6DE1B370F00DQ28079939-C9BB95A4-93CA-4616-B2A4-F4552FA0F59FQ28083239-94542CDB-46E2-42E3-B87A-3AD184FD0D37Q28534577-3DAD81F2-CC35-4682-8FA8-8187EDEEEA5CQ33655128-7337A9F8-5121-41E0-B523-0373FB7A16EAQ33684384-B1EC14B4-C572-437C-B0B5-A06839E89AFEQ33815063-7E9E43F4-0209-4F82-A7F1-932CD5C7C5F8Q33938441-F4D89A5F-DB57-47A0-AA1F-5625B5B68351Q34432733-C9AA3E36-2230-4F58-8F91-F77BB9D840D4Q34452586-E28CFC75-9ED4-4794-9BFF-05FCE8EC7D29Q34497467-A7E18021-B403-4128-B2D0-71321059C2A7Q34646038-8C86B876-8A76-470A-85CC-DAB6B4FA30B7Q35196345-87E0BA51-3AD2-42D2-A29E-0CF5862AAB79Q35200727-F506A359-599F-447A-8565-2DD6DD56B530Q35207787-102613F9-2A82-4F1C-9AAC-B6C95003F68EQ35207885-341B5569-BD3A-47F5-A110-A574ED9A7787Q35742451-B8E6D520-D4F3-498C-9A98-556A45F9BF76Q36317864-61CB1970-30E3-4F69-86FF-5D4F46DE5623Q36660669-12EC64B2-EF5C-4440-ACD8-B33A9910B26AQ36741917-059F7845-D762-4812-95F6-BFA873409D8DQ36834883-9786BFC7-A30E-4BE9-8E9A-75C470A30742Q37052272-4465F560-6235-49D4-A40C-34EF12416B9FQ37128041-168D6878-4AB8-4209-8A70-89C92B500CACQ37706284-AAF44FDF-FF19-4837-A642-9C4DA8854D92Q37738403-DAC47A8A-8700-47C1-ABEA-DC8A858A6614Q38199478-7659CCBB-7766-412D-A7A2-FCB78D677083Q38224482-1A3261C8-BD41-49C6-9E93-366DAB9D29BDQ38264616-9CB7C984-5F33-4D60-96C1-D5A6898F8C3EQ38673986-2A80B97E-861D-4EFA-9305-6B3683EDEE3AQ38833038-85A2E45B-2FB4-4A9F-82F6-247CE169169DQ38860011-8E916318-4E20-4F6A-AA76-A034A16BF7BDQ38972669-EEA682C9-6647-4338-92A2-F3E2127930A0Q39277085-224B3636-0A1C-476F-9E78-7CE042035B83Q41959315-0F092CFA-0A60-438B-A9D9-4327D721B297Q45814614-C5946996-DC92-4F2B-A47C-6235702C98A4Q46213211-23F12795-5D4C-4855-8178-74EDFC56478CQ46505392-7D3B6BFA-EA96-4713-AFB6-68E6E5D89D84Q47160671-C36F28CA-3EAD-45B6-AA18-E4B1697464B8Q47781357-5A99CFFB-417D-4099-94AB-709A6B72C05FQ48182109-A2F4D2AC-AB9B-4135-BAE6-D704AC85A67E
P2860
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@ast
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@en
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@nl
type
label
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@ast
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@en
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@nl
prefLabel
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@ast
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@en
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@nl
P2093
P2860
P356
P1433
P1476
Clinical responses to EGFR-tyr ...... apy: a retrospective analysis.
@en
P2093
Hirohisa Yoshizawa
Hiroshi Kagamu
Hiroshi Tanaka
Ichiei Narita
Jun Koshio
Junko Baba
Junta Tanaka
Kosuke Ichikawa
Satoshi Watanabe
P2860
P2888
P356
10.1186/1471-2407-11-1
P407
P577
2011-01-01T00:00:00Z
P5875
P6179
1005272639